Submitted Projects
Cell and Gene Therapy Challenge
New Vaccine Challenge
COPD/Asthma
CNS
AMD
Diabetes
Pediatric Drug
Pediatric Drug
Project ID: PED101
Category: Pediatric Drug
Keyword: Novel bioactive lipid compounds
Project PED101 develops new medicines for unmet needs in dermatological diseases. The compounds under development are based on a novel bioactive lipid platform. These molecules are crucial to the pathways of several conditions including skin disorders such as atopic dermatitis (AD). The Company’s lead compound is being explored clinically as both a topical cream for mild to moderate AD (Phase 3) and separately as an oral capsule in moderate to severe AD (Phase 2b). DS holds multiple patents and pending applications protecting the product and its clinical uses.
Indications: Atopic Dermatitis in
Children and Adolescents
Stage: Clinical Phase II/Phase III
Partnering Objectives: Fundraisingd US$48 million for Phase III of the experiment
Country: Ireland
Project ID: PED102
Category: Pediatric Drug
Keyword: Glycopyrronium Bromide Liquid
The company develops product Glycopyrronium Bromide is proven to be effective and well-tolerated in treating severe hypersalivation in children and adolescents with cerebral palsy or other neurological conditions; it is available in a liquid formulation to provide maximal dosing flexibility and tolerability. Licensed indications include: Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders
Indications: Excessive saliva
production
Stage: public listed
Project ID: PED103
Category: Pediatric Drug
Project ID: CGT100
Category: Cell and Gene Therapy Challenge
Keywords: ACE2 Inhibitor
Our apelin therapy provides the evolutionary solution to inhibit viral replication and downstream ACE2 downregulation at the receptor level.
Indications: Heart failure, diabetes, pulmonary hypertension
Stage: IND
Partnering Objective: Fundraising, Co-development
Project ID: CGT101
Category: Cell and Gene Therapy Challenge
Project ID: CGT102
Category: Cell and Gene Therapy Challenge
Company is developing two platform technologies, gene therapy and small molecule therapy, including 4 gene therapies and one small molecule in the pipeline, to treat a variety of neurological disorders including stroke, Alzheimer’s disease, ALS, spinal cord injury, Parkinson’s disease, and Huntington’s disease.
Category: Cell and Gene Therapy Challenge
Category: Cell and Gene Therapy Challenge
According to limited available data two thirds of 2019-nCoV patients have lymphopenia and many of those who died from the virus had co-morbidities or were >50 years old. From previous coronavirus epidemics we know that immunocompromised individuals are more likely to get infected and die from the disease. Therefore therapies that enhance immune function may have effect in decreasing mortality and severity of disease. PO was extensively studied in Russia as a single agent immune modulator in patients with infectious diseases in multiple trials. Results of these studies make PO in our view a very promising molecule for treating 2019-nCoV patients.
In several clinical trials in cancer patients receiving chemotherapy PO administration led to significant increase in blood CD4 and CD8 cell counts. In HIV infected patients with pneumonia PO administration in combination with antibiotics led to drastic decrease of duration of symptoms in comparison with antibiotics alone. CD4 counts in these patients were also increased due to PO action. This effect was repeated in two-year old pneumonia patients (young children have underdeveloped immunity). In patients with primary immunodeficiency PO shortened the duration of infection disease episodes and increased the duration of remission. The inclusion of PO in the treatment of patients with acute pancreatitis reduced mortality by 2 times. It is worth mentioning that safety of PO was proven in more than 20 clinical trials and were conducted in Russia and in other countries, including Slovakia. In all clinical studies and for many years of use in clinical practice Polyoxidonium showed a good safety profile.
We believe that PO should be studied as an immune enhancing agent in 2019-nCoV patients due to its effect on lymphocyte count and on the duration of pneumonia in immunocompromised patients. Therefore therapies that enhance immune function may have effect in decreasing mortality and severity of disease in 2019-nCoV patients.
We suggest to organize collaborative study with Chinese virologists currently fighting nCoV outbreak.
hepatitis B on long term treatment with nucleotide/nucleoside antivirals. Readout of this trial is expected in 2021. The product is available for outlicensing or co-development. We are also seeking funding for worldwide clinical development.”
The company’s Pulsehaler™ technology is the first and only treatment to directly re-open the collapsed small airways of COPD patients, thereby reducing breathlessness and improving patient’s ability to walk. The Pulsehaler™ technology produces unique multi-frequency, air pressure pulses which are carried into the lungs, gently prying open the airways, lowering the viscosity of mucus that could re-plug the airway, and stenting the airway open to allow the airway clearance mechanisms to function properly. The technology was clinically proven in a double blind controlled study, and published in the peer reviewed Journal of COPD. Our technology is protected by 6 patent families, with 15 issued patents and 9 additional pending patents.
The company’s technology pipeline also includes patented designs for improving delivery of inhaled drugs. This technology was clinically proven to deliver drugs more than 200% better than traditional nebulizers, with significant improvements in lung function. We have begun initial discussions with Pharma companies to partner in the development of Best-in-Class inhaled therapies, including COPD, Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension.
Posiphen® inhibits APP, tau and aSYN in tissue culture cells, mice as well as in humans. Posiphen® also shows promise in Huntington’s disease, Down Syndrome, Traumatic Brain Injury, and Post Operative Cognitive Decline. So far three clinical studies have been conducted with Posiphen®.
Dia